September 2022 in “Journal of the American Academy of Dermatology” The registry showed that tofacitinib is promising for treating hair loss in children with alopecia areata, but more research is needed.
April 2010 in “Nature Reviews Urology” January 2011 in “Bloomsbury Academic eBooks”
July 2022 in “International Journal of Trichology” Tofacitinib helped an 8-year-old child recover from a type of hair loss that is hard to treat.
August 2022 in “Dermatology Online Journal” Oral and topical tofacitinib can effectively treat severe hair loss with minimal side effects.
1 citations
,
April 2017 in “Journal of Investigative Dermatology” Tofacitinib may help regrow hair in severe alopecia areata, but results differ greatly between people.
5 citations
,
March 2020 in “Thoracic Cancer” CT-707 is effective and safe for treating certain Chinese lung cancer patients.
86 citations
,
June 2018 in “Cochrane library” Mycophenolate mofetil may improve lupus nephritis remission more than cyclophosphamide but with uncertain safety.
April 2024 in “JEADV clinical practice” Upadacitinib significantly improved both rheumatoid arthritis and alopecia areata in a patient.
March 2026 in “Korean Journal of Clinical Pharmacy” In 2024, the FDA approved 50 new drugs, including treatments for hair loss, anemia, high blood pressure, and Alzheimer's.
June 2020 in “Journal of Investigative Dermatology” Getting insurance to cover the hair loss treatment tofacitinib is hard because it's not officially approved for that use.
58 citations
,
March 2019 in “Frontiers in Pharmacology” Wedelolactone may help treat lung fibrosis by reducing inflammation and lung damage.
January 2024 in “Clinical and Experimental Dermatology” Baricitinib helps treat severe hair loss in people over 65.
2 citations
,
September 2023 in “Journal of the American Academy of Dermatology” Baricitinib is a safe and effective treatment for severe alopecia areata.
39 citations
,
May 2006 in “Molecular Plant-Microbe Interactions” Fusaric acid may help control Orobanche ramosa by activating plant defenses.
November 2025 in “SKIN The Journal of Cutaneous Medicine” Baricitinib is effective and safe for treating severe alopecia areata for up to 5 years.
Low-dose sorafenib can cause severe facial acne, treatable with topical medication.
79 citations
,
September 2018 in “Dermatologic therapy” Oral tofacitinib can significantly improve recalcitrant lichen planopilaris.
222 citations
,
September 2016 in “JCI insight” Tofacitinib is safe and effective for severe alopecia areata, but hair loss may return 2 months after stopping treatment.
155 citations
,
September 2008 in “British journal of dermatology/British journal of dermatology, Supplement” FFA is more common in postmenopausal women, can affect younger women, and may stabilize over time.
9 citations
,
April 2018 in “Journal of Dermatological Treatment” Tofacitinib improves nail conditions in patients with severe hair loss and does not affect hair regrowth.
37 citations
,
December 2020 in “PLANT PHYSIOLOGY” A mutant FERONIA gene affects root hair growth at high temperatures.
7 citations
,
March 2021 in “Journal of the American Academy of Dermatology” Tofacitinib can regrow hair in alopecia areata patients, but some may experience flares during treatment.
11 citations
,
January 2020 in “Dermatologica Sinica” Tofacitinib helps regrow hair in severe alopecia patients, but more research is needed.
4 citations
,
April 2016 in “Journal of The American Academy of Dermatology” A patient with advanced kidney cancer and no hepatitis C developed skin inflammation due to a drug called interferon alpha-2a.
9 citations
,
January 2018 in “Journal of the European Academy of Dermatology and Venereology” A male patient developed frontal fibrosing alopecia after antiandrogen therapy for prostate cancer.
August 2020 in “Ugeskrift for Læger” A man with severe hair loss regrew all his hair using tofacitinib and stayed healthy for a year.
98 citations
,
January 2013 in “Journal of The American Academy of Dermatology” Dutasteride may help stabilize Frontal Fibrosing Alopecia, but more research is needed.
42 citations
,
February 1998 in “The Journal of Steroid Biochemistry and Molecular Biology” PNU 157706 is a more effective treatment than finasteride for conditions caused by DHT, like enlarged prostate and hair loss.
January 2025 in “Reactions Weekly”